Articulinx, Inc., a Cupertino, CA-based medical device company developing a minimally-invasive approach for the treatment of osteoarthritis, closed a $10m Series B financing led by US Venture Partners.
Existing investor De Novo Ventures completed the round.
Funds will be used to continue development of the Articulinx spacer technology, and to fund ongoing operations.
The company’s first product, the Articulinx CMC Spacer, is implanted through a small incision under local anesthesia. The device acts as a spacer to separate bones in joints where the articular cartilage has degenerated.